Recombinant Anti-HER1 x Anti-HER3 Bispecific Antibody (scIgG) (SCIGG-165)

Recombinant Anti-HER1 x Anti-HER3 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-HER1 and anti-HER3 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Head and neck cancer; Colorectal cancer therapy.

Datasheet INQUIRY

Specifications

Targets

HER1 & HER3

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Head and neck cancer; Colorectal cancer

Targets

Target 1

HER1

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Target 2

HER3

Gene ID

2065

UniProt ID

P21860

Alternative Names

ERBB3; erb-b2 receptor tyrosine kinase 3; HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; proto-oncogene-like protein c-ErbB-3; human epidermal growth factor receptor 3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-HER1 x Anti-HER3 Bispecific Antibody (scIgG) (SCIGG-165). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-HER1 x Anti-HER3 Bispecific Antibody (scIgG) (CAT#: SCIGG-165)

Specifications

Targets

Customer Reviews and Q&As